Press Releases

Date Title
September 28, 2021
Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial
Full year data reinforce strong safety profile consistent with previous trials of ONS-5010 and with prior published data on ophthalmic bevacizumab Full data to be presented at American Academy of Ophthalmology’s Retina Subspecialty Meeting, RET13 - Section X: Late Breaking Developments, Part II on
September 21, 2021
Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
Live fireside chat with C. Russell Trenary, President and CEO of Outlook Therapeutics on Tuesday, September 28 at 2:00 PM ET ISELIN, N.J. , Sept. 21, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved
September 13, 2021
Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference
ISELIN, N.J. , Sept. 13, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the presentation of safety data from
September 8, 2021
Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
ISELIN, N.J. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C.
August 13, 2021
Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update
Reported positive, statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD) On track to submit new U.S.
August 11, 2021
Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference
Russell Trenary , President and Chief Executive Officer of Outlook Therapeutics , to participate in The Greatest Unmet Needs Facing Ophthalmology Today panel on Tuesday, August 17 th at 9:00 AM ET ISELIN, N.J. , Aug. 11, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.
August 3, 2021
Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
In NORSE TWO, ONS-5010 achieved statistically significant and clinically relevant primary (p = 0.0052) and key secondary (p = 0.0043) efficacy endpoints with 41% of subjects gaining at least 15 letters In NORSE TWO, ONS-5010 was safe and well tolerated Management to host conference call and webcast
July 7, 2021
Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer
Experienced executive with a track-record of successful eye care product launches Appointment reflects Outlook Therapeutics’ dedication to transition to commercial-stage company ISELIN, N.J. , July 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.
June 14, 2021
Outlook Therapeutics Announces Inclusion in the Russell 2000® Index
ISELIN, N.J. , June 14, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that as part of the annual
June 8, 2021
Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial
Topline readout of data from NORSE TWO targeted for calendar Q3 2021 New Biologics License Application (BLA) filing anticipated in calendar Q1 2022 ISELIN, N.J. , June 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to
Displaying 11 - 20 of 136